162 related articles for article (PubMed ID: 11403208)
1. Species dependence for binding of small molecule agonist and antagonists to the C5a receptor on polymorphonuclear leukocytes.
Woodruff TM; Strachan AJ; Sanderson SD; Monk PN; Wong AK; Fairlie DP; Taylor SM
Inflammation; 2001 Jun; 25(3):171-7. PubMed ID: 11403208
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterization of antagonists of the C5a receptor.
Paczkowski NJ; Finch AM; Whitmore JB; Short AJ; Wong AK; Monk PN; Cain SA; Fairlie DP; Taylor SM
Br J Pharmacol; 1999 Dec; 128(7):1461-6. PubMed ID: 10602324
[TBL] [Abstract][Full Text] [Related]
3. Response-selective C5a agonists: differential effects on neutropenia and hypotension in the rat.
Short AJ; Paczkowski NJ; Vogen SM; Sanderson SD; Taylor SM
Br J Pharmacol; 1999 Oct; 128(3):511-4. PubMed ID: 10516626
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of C5a-induced neutrophil chemotaxis and macrophage cytokine production in vitro by a new C5a receptor antagonist.
Haynes DR; Harkin DG; Bignold LP; Hutchens MJ; Taylor SM; Fairlie DP
Biochem Pharmacol; 2000 Sep; 60(5):729-33. PubMed ID: 10927032
[TBL] [Abstract][Full Text] [Related]
5. Biologically active conformer of the effector region of human C5a and modulatory effects of N-terminal receptor binding determinants on activity.
Finch AM; Vogen SM; Sherman SA; Kirnarsky L; Taylor SM; Sanderson SD
J Med Chem; 1997 Mar; 40(6):877-84. PubMed ID: 9083476
[TBL] [Abstract][Full Text] [Related]
6. The influence of Lys68 in decepeptide agonists of C5a on C5a receptor binding, activation and selectivity.
Vogen SM; Finch AM; Wadi SK; Thatcher J; Monk PN; Taylor SM; Sanderson SD
J Pept Res; 1999 Jan; 53(1):8-17. PubMed ID: 10195437
[TBL] [Abstract][Full Text] [Related]
7. Modulation of ligand selectivity by mutation of the first extracellular loop of the human C5a receptor.
Cain SA; Woodruff TM; Taylor SM; Fairlie DP; Sanderson SD; Monk PN
Biochem Pharmacol; 2001 Jun; 61(12):1571-9. PubMed ID: 11377387
[TBL] [Abstract][Full Text] [Related]
8. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a.
Finch AM; Wong AK; Paczkowski NJ; Wadi SK; Craik DJ; Fairlie DP; Taylor SM
J Med Chem; 1999 Jun; 42(11):1965-74. PubMed ID: 10354404
[TBL] [Abstract][Full Text] [Related]
9. Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity.
March DR; Proctor LM; Stoermer MJ; Sbaglia R; Abbenante G; Reid RC; Woodruff TM; Wadi K; Paczkowski N; Tyndall JD; Taylor SM; Fairlie DP
Mol Pharmacol; 2004 Apr; 65(4):868-79. PubMed ID: 15044616
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of immune-complex mediated dermal inflammation in rats following either oral or topical administration of a small molecule C5a receptor antagonist.
Strachan AJ; Shiels IA; Reid RC; Fairlie DP; Taylor SM
Br J Pharmacol; 2001 Dec; 134(8):1778-86. PubMed ID: 11739255
[TBL] [Abstract][Full Text] [Related]
11. Differential activities of decapeptide agonists of human C5a: the conformational effects of backbone N-methylation.
Vogen SM; Paczkowski NJ; Kirnarsky L; Short A; Whitmore JB; Sherman SA; Taylor SM; Sanderson SD
Int Immunopharmacol; 2001 Nov; 1(12):2151-62. PubMed ID: 11710544
[TBL] [Abstract][Full Text] [Related]
12. Antagonistic peptides against human anaphylatoxin C5a.
Kaneko Y; Okada N; Baranyi L; Azuma T; Okada H
Immunology; 1995 Sep; 86(1):149-54. PubMed ID: 7590876
[TBL] [Abstract][Full Text] [Related]
13. Effects of a new C5a receptor antagonist on C5a- and endotoxin-induced neutropenia in the rat.
Short A; Wong AK; Finch AM; Haaima G; Shiels IA; Fairlie DP; Taylor SM
Br J Pharmacol; 1999 Feb; 126(3):551-4. PubMed ID: 10188960
[TBL] [Abstract][Full Text] [Related]
14. Cloning and characterization of the guinea pig C5a anaphylatoxin receptor: interspecies diversity among the C5a receptors.
Fukuoka Y; Ember JA; Yasui A; Hugli TE
Int Immunol; 1998 Mar; 10(3):275-83. PubMed ID: 9576615
[TBL] [Abstract][Full Text] [Related]
15. Structure-function relationships of human C5a and C5aR.
Huber-Lang MS; Sarma JV; McGuire SR; Lu KT; Padgaonkar VA; Younkin EM; Guo RF; Weber CH; Zuiderweg ER; Zetoune FS; Ward PA
J Immunol; 2003 Jun; 170(12):6115-24. PubMed ID: 12794141
[TBL] [Abstract][Full Text] [Related]
16. A new small molecule C5a receptor antagonist inhibits the reverse-passive Arthus reaction and endotoxic shock in rats.
Strachan AJ; Woodruff TM; Haaima G; Fairlie DP; Taylor SM
J Immunol; 2000 Jun; 164(12):6560-5. PubMed ID: 10843715
[TBL] [Abstract][Full Text] [Related]
17. Direct binding of a fragment of the Wiskott-Aldrich syndrome protein to the C-terminal end of the anaphylatoxin C5a receptor.
Tardif M; Brouchon L; Rabiet MJ; Boulay F
Biochem J; 2003 Jun; 372(Pt 2):453-63. PubMed ID: 12600272
[TBL] [Abstract][Full Text] [Related]
18. Restricted ability of group B streptococcal C5a-ase to inactivate C5a prepared from different animal species.
Bohnsack JF; Chang JK; Hill HR
Infect Immun; 1993 Apr; 61(4):1421-6. PubMed ID: 8454345
[TBL] [Abstract][Full Text] [Related]
19. Site-directed mutagenesis of conserved charged residues in the helical region of the human C5a receptor. Arg2O6 determines high-affinity binding sites of C5a receptor.
Raffetseder U; Röper D; Mery L; Gietz C; Klos A; Grötzinger J; Wollmer A; Boulay F; Köhl J; Bautsch W
Eur J Biochem; 1996 Jan; 235(1-2):82-90. PubMed ID: 8631370
[TBL] [Abstract][Full Text] [Related]
20. [Small increase of CR1 and CR3 by C5a-receptors on polymorphonuclear leukocytes in systemic lupus erythematosus].
Doi T; Takemura S; Onodera H; Ueda M; Deguchi M; Nakahara R; Ichio N; Nakanishi S; Seto N; Yanagida K; Kondo M
Arerugi; 1997 Nov; 46(11):1108-13. PubMed ID: 9436327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
